Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review

March 2019 | 64 pages | ID: CB9378AE000EN
GlobalData

Abstracts

Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Mar 11,2019 Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11,2019 Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04,2019 Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01,2019 BMS faces shareholder opposition to $74bn Celgene acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Celgene Corp - Key Facts
Celgene Corp - Key Employees
Celgene Corp - Key Employee Biographies
Celgene Corp - Major Products and Services
Celgene Corp - History
Celgene Corp - Company Statement
Celgene Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Celgene Corp - Business Description
Product Category: Abraxane
Overview
Performance
Product Category: Azacitidine for injection
Overview
Performance
Product Category: Idhifa
Overview
Performance
Product Category: Istodax
Overview
Performance
Product Category: Otezla
Overview
Performance
Product Category: Pomalyst/Imnovid
Overview
Performance
Product Category: Revlimid
Overview
Performance
Product Category: Thalomid
Overview
Performance
Product Category: Vidaza
Overview
Performance
Product Category: Other Revenue
Performance
Product Category: Product Revenue
Performance
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Celgene Corp - SWOT Analysis
SWOT Analysis - Overview
Celgene Corp - Strengths
Celgene Corp - Weaknesses
Celgene Corp - Opportunities
Celgene Corp - Threats
Celgene Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 11, 2019: Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11, 2019: Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04, 2019: Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01, 2019: BMS faces shareholder opposition to $74bn Celgene acquisition
Feb 26, 2019: Celgene Corporation Announces Key Regulatory Updates for REVLIMIDÂ in Lymphoma and Luspatercept in MDS and BetaThalassemia
Feb 25, 2019: Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against Celgene Corporation (CELG) And Its Directors
Feb 20, 2019: Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
Feb 05, 2019: Lyfebulb and Celgene announce call for innovation challenge applications to address unmet needs in multiple sclerosis
Feb 05, 2019: Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
Jan 31, 2019: Celgene reports fourth quarter and full year 2018 operating and financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Celgene Corp, Key Facts
Celgene Corp, Key Employees
Celgene Corp, Key Employee Biographies
Celgene Corp, Major Products and Services
Celgene Corp, History
Celgene Corp, Other Locations
Celgene Corp, Subsidiaries
Celgene Corp, Key Competitors
Celgene Corp, Ratios based on current share price
Celgene Corp, Annual Ratios
Celgene Corp, Annual Ratios (Cont...1)
Celgene Corp, Annual Ratios (Cont...2)
Celgene Corp, Interim Ratios
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Celgene Corp, Performance Chart (2014 - 2018)
Celgene Corp, Ratio Charts
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Sanofi
Merck & Co Inc
Eisai Co Ltd
Johnson & Johnson
Genentech Inc
Abbott Laboratories
Eli Lilly and Co
Biogen Inc
Takeda Pharmaceutical Co Ltd
Novartis AG
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
AstraZeneca Plc
Immunomedics Inc
Amgen Inc